KFF's The Business of Health with Chip Kahn

Bench to Bedside at AI Speed

48 min · 16. juni 2026
Billede af episoden Bench to Bedside at AI Speed

Description

How can AI determine who gets matched to new therapies, who is identified for clinical trials, and how patient tracking is scaled across large populations? Chip is joined by Dr. A.J. Blood, a practicing cardiologist at Brigham and Women's Hospital and the co-founder and Chief Executive Officer of AIwithCare, a startup company that delivers AI-enabled solutions for research, clinical operations, and patient care. They discuss the role of AI in identifying patients for clinical trials and new therapies—which is typically a critical bottleneck in drug development—as well as how to ensure clinical trials are representative. Also, Dr. Blood shares insights from his extensive research background and the tool, RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review), designed to enhance patient recruitment for clinical trials by efficiently sifting through complex medical data. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

Comments

0

Be the first to comment

Sign up now and become a member of the KFF's The Business of Health with Chip Kahn community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

15 episodes

episode The AI Arms Race in Administrative Health Care artwork

The AI Arms Race in Administrative Health Care

Caroline Pearson, executive director of the Peterson Health Technology Institute (PHTI) and the Peterson Center on Healthcare, joins Chip to discuss who really benefits as AI moves into health care's back office. A quiet arms race is underway — providers deploying AI to code, bill, and capture revenue and insurers deploying it right back to review, deny, and hold the line. The open question is whether any of this lowers what the country actually spends or just speeds up the fight over the dollar. Pearson brings a rare vantage: PHTI runs rigorous, independent evaluations of health technology — from a now-famous assessment that found digital diabetes tools didn't lower the total cost of care, to its own examination of the administrative AI arms race in prior authorization and medical billing. She and Chip dig into whether AI can deliver better care and real savings, or simply more activity — and how incentives and policy decide which way it breaks. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

14. juli 202649 min
episode AI: Show Me the Outcomes artwork

AI: Show Me the Outcomes

Chip talks with Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, which delivers value-based care to more than 100,000 Medicaid and dual-eligible members across ten states, many of them people of color managing chronic conditions. Ajayi makes a pointed case: Roughly 60 percent of health care AI investment goes to billing, coding, and risk adjustment — making sure someone gets paid — while only a fraction goes to delivering care. If we continue to concentrate AI there, she warns, it will drive up cost without improving outcomes. She says there is a better way — AI built for care can lower costs by improving care for those hardest to reach. She and Chip discuss what that looks like and how Cityblock is using AI now to improve care and the patient experience for its members. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

30. juni 202635 min
episode Is AI (Still) Biased? artwork

Is AI (Still) Biased?

In this episode, Dr. Ziad Obermeyer joins Chip to talk about AI bias in patient management, including how far the health care industry has come since his groundbreaking research that revealed alarming biases in a widely used algorithm that underestimated the health needs of Black patients. The discussion emphasizes that while AI can analyze data with remarkable precision, it is the context surrounding that data that ultimately determines its efficacy, usefulness, and fairness. Dr. Obermeyer is an emergency department physician, researcher, co-founder of Nightingale Open Science [https://docs.ngsci.org/access-data] and Dandelion [https://dandelionhealth.ai/], and associate professor at the UC Berkeley School of Public Health and the College of Computing, Data Science, and Society. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

23. juni 202655 min